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Antimicrobial peptides (AMPs) are a potential alternative to classical antibiotics that are yet
to achieve a therapeutic breakthrough for treatment of systemic infections. The antibacterial
potency of pleurocidin, an AMP from Winter Flounder, is linked to its ability to cross bacterial
plasma membranes and seek intracellular targets while also causing membrane damage.
Here we describe modification strategies that generate pleurocidin analogues with sub-
stantially improved, broad spectrum, antibacterial properties, which are effective in murine
models of bacterial lung infection. Increasing peptide–lipid intermolecular hydrogen bonding
capabilities enhances conformational flexibility, associated with membrane translocation, but
also membrane damage and potency, most notably against Gram-positive bacteria. This
negates their ability to metabolically adapt to the AMP threat. An analogue comprising D-
amino acids was well tolerated at an intravenous dose of 15 mg/kg and similarly effective as
vancomycin in reducing EMRSA-15 lung CFU. This highlights the therapeutic potential of
systemically delivered, bactericidal AMPs.
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The 2016 review on antimicrobial resistance
1 (AMR) pre-
dicts that, unless action is taken, around 10 million deaths
per year will be attributable to AMR by the year 2050.
Action recommended by the review is twofold: (1) that the
inappropriate use of existing antimicrobials should be reduced so
that their utility endures for longer and; (2) new antimicrobials
must be made available that are effective against drug-resistant
bacteria. The pipeline of new antibiotics is limited however, hence
the potential of numerous alternatives to antibiotics—“non-
compound approaches (i.e. products other than classic anti-
bacterial agents) that target bacteria or approaches that target the
host”—is being actively investigated2.
Commissioned by the Wellcome Trust, a pipeline portfolio
review of alternatives to antibiotics recommends “strong support
for funding while monitoring for breakthrough insights regarding
systemic therapy” for a tier of approaches that include AMPs2.
The review presents the prevailing wisdom that AMPs are
unsuited for systemic administration as they are poorly tolerated
in animal models and susceptible to degradation. This sub-
stantially limits the scope of infection settings that are tractable to
AMPs and hence their future development. There is an urgent
need therefore to identify AMPs that are sufficiently potent
against antibiotic resistant bacteria and well tolerated in vivo such
that they are effective when delivered intravenously.
AMPs are a well-studied subset of a group of peptides that
contribute to innate immunity, in a diverse range of organisms,
through direct antimicrobial action and/or host defence
regulation3,4. Identified in the Winter Flounder5, Pleuronectes
americanus, pleurocidin is a potent AMP with broad spectrum
antibacterial activity that acts by damaging the plasma mem-
brane6, with activity that is dependent on their ability to adopt an
amphipathic α-helix conformation7. It is now well established,
however, that many AMPs can disrupt bacterial cell metabolism,
in addition to, or in place of, their well-known membrane
damaging action8. Pleurocidin is one such AMP and previous
work supports the view that its high potency, at least against
Gram-negative bacteria, such as Escherichia coli, is linked to its
ability to cross the bacterial plasma membrane and penetrate
within bacteria to attack intracellular targets9,10. Importantly, the
ordered α-helix conformation that pleurocidin adopts in many
membrane mimics or models is less apparent in those models that
most closely represent a Gram-negative bacterial cytoplasmic
membrane11,12. The increased conformational flexibility, detected
when pleurocidin binds to such membranes, affords greater
ability to penetrate into the hydrophobic core of the lipid
bilayer12, a property that we infer is critical to the potency
associated with its intracellular penetration.
Strategies that increase the conformational flexibility of pleur-
ocidin, when binding to model membranes, are likely to sub-
stantially alter its biological properties. Here we report the results
of two such strategies. First, we hypothesised that substituting less
bulky and less hydrophobic alanines for valines (both Val12 and
Val16; pleurocidin-VA Table 1) located near to two key glycine
residues (respectively Gly13 and Gly17) would have substantial
impact on conformational flexibility in pleurocidin12,13. Secondly,
we hypothesised that substituting arginine for each of the four
lysine residues (Lys7, Lys8, Lys14, Lys18; pleurocidin-KR Table 1)
would directly increase hydrogen bonding between the peptide
and the lipid headgroups, shifting the balance away from intra-
molecular hydrogen bonding that stabilises more ordered α-helix
conformations.
Having solved the structures of the new analogues, we used a
combination of both time-resolved and steady-state biophysical
methods to determine the impact of the modifications on the
membrane interaction to determine whether the modifications
enhance and/or alter the peptide properties and bactericidal
mechanisms of action. We evaluated the in vitro toxicity against
mammalian cells and antibacterial performance against a panel of
both Gram-negative and Gram-positive bacterial pathogens for the
three pleurocidin analogues, and their all D-amino acid enantio-
mers, in both bacteriological and mammalian cell culture media.
Further, we used an NMR metabolomic approach to investigate:
(1) whether epidemic methicillin-resistant Staphylococcus aureus
(EMRSA-15 NCTC 13616) or Pseudomonas aeruginosa RP73
distinguish between the (D-enantiomer) analogues to understand
whether altered membrane interaction properties are manifested
when challenging pathogens in vitro and; (2) whether altering the
metabolic strategy of the bacteria renders them more or less sus-
ceptible to D-pleurocidin or its analogues. Finally, the therapeutic
ability of D-pleurocidin-KR was demonstrated in a murine model
of EMRSA-15 lung infection, when delivered intravenously.
Results
Peptide–lipid hydrogen bonding is directly and indirectly
altered in pleurocidin analogues. In designing both in silico and
in vitro experiments it is important to consider the contribution
of the three histidines in pleurocidin, the charge state of which
will have substantial impact on the interaction of the peptide with
membranes of varying anionic charge density. According to the
Gouy-Chapman model, the effective pH will be reduced further,
the greater the anionic charge density at a membrane surface.
Molecular dynamics (MD) simulations were constructed using
structures of pleurocidin or its analogues determined in anionic
detergent micelles as a first approximation of the negatively
charged and amphipathic surface of a bacteria plasma membrane
(Supplementary Fig. 1 and Supplementary Table 1). Previously we
ensured histidine residues were positively charged in MD
simulations, based on the observations of pH-dependent dis-
ordering of mixed zwitterionic-anionic membranes that suggested
at least partial protonation at neutral pH12. Here we investigated
pH-dependent changes in conformational disorder (Supplemen-
tary Fig. 2) using far-UV circular dichroism (CD) and determined
no pH dependency in anionic 1-palmitoyl-2-oleoyl-sn-glycero-3-
phospho-(1′-rac-glycerol) (POPG) membranes in the range tested.
Again however, in the mixed zwitterionic-anionic model mem-
branes an increase in conformational disorder was observed on
Table 1 Peptides sequences, biophysical characteristics and concentration of peptide necessary to start membrane activity in
electrophysiology experiments.
Peptide Sequence H (μH)α (μH)3–11 Peptide concentration (µM)
DPhPE/DPhPG DPhPG
Pleurocidin GWGSFFKKAAHVGKHVGKAALTHYL 0.421 0.309 0.340 10 5
Pleurocidin-KR GWGSFFRRAAHVGRHVGRAALTHYL 0.418 0.311 0.342 10 7.5
Pleurocidin-VA GWGSFFKKAAHAGKHAGKAALTHYL 0.348 0.278 0.323 – 2.5
All peptides were amidated at the C-terminus. Hydrophobicity (H) and hydrophobic moment assuming α (µH)α or 3–11 (µH)3-11 helix secondary structure were calculated using HeliQuest66.
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lowering the bulk pH. The anionic POPG bilayers are simple
models of the plasma membrane of Gram-positive bacteria while
the mixed zwitterionic-anionic bilayers model the corresponding
structures in Gram-negative bacteria14,15. Therefore, while here we
have performed MD simulations both with all histidines carrying a
positive or no overall charge, the simulations of pleurocidin and its
analogues in anionic POPG with positively charged histidine are
likely a better model of the interaction with the Gram-positive
plasma membrane. In contrast, the best model of the Gram-
negative plasma membrane interaction lies somewhere between
the simulations with the two differing charges states.
The importance of the histidine charge state in understanding
the interaction with anionic or mixed anionic/zwitterionic lipid
bilayers can be seen by comparing contributions from each
residue in the peptide to hydrogen bonding to lipids (Fig. 1). In
pleurocidin, His11 and His15 make important hydrogen bonding
contributions to 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoetha-
nolamine (POPE)/POPG bilayers but only when carrying a
positive charge (Fig. 1d, e). When pleurocidin binds to a
uniformly anionic bilayer surface the contribution from His11
is enhanced and a contribution from His23 is registered (Fig. 1f).
Bulk pH and anionic surface charge density can therefore
combine to create a selectivity switch, affecting both the
probability of each of the three histidines carrying a positive
charge but also the nature of the non-covalent interaction
between peptide and lipids—much less peptide to lipid hydrogen
bonding can be expected for pleurocidin attempting to bind to a
zwitterionic surface at neutral and much more when addressing
Fig. 1 Hydrogen bonding from peptide to lipids is altered in pleurocidin analogues and affected by histidine charge state. Total (a–c) or residue specific
(d–l) peptide–lipid hydrogen bonds are shown as a function of time for pleurocidin and its two analogues in three representative MD simulations; POPE/
POPG bilayers with positively charged histidines (a, d, g, j), POPE/POPG bilayers with uncharged histidines (b, e, h, k) and POPG bilayers with positively
charged histidines (c, f, i, l). Residue specific data are shown for pleurocidin (d–f), pleurocidin-KR (g–i) and pleurocidin-VA (j–l).
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an anionic surface in mildly acidic conditions. These two
extremes, crudely, represent, respectively, the plasma membranes
of a host cell and a bacterial pathogen at a site of infection16,17.
Interestingly, pleurocidin-VA is particularly sensitive to the
charge state of the three histidines as hydrogen bonding via Lys18
is also attenuated on binding to the POPE/POPG bilayer when
the histidines do not carry a positive charge. His11, when
positively charged, makes a more substantial contribution to
hydrogen bonding than in the parent peptide (Fig. 1j, k). In
contrast, when binding to the anionic POPG bilayer, hydrogen
bonding via His23 is much stronger, and via His11 much weaker,
than in pleurocidin (Fig. 1f, l). Substitution of Val12 and Val16 by
alanine therefore has an indirect effect on peptide–lipid hydrogen
bonding that is felt in segments of the peptide that are distant
from the flexible region around Gly13 and Gly17. Substitution of
arginines for the four lysines has a direct effect on peptide–lipid
hydrogen bonding. Pleurocidin-KR forms approximately one and
a half times as many hydrogen bonds with the bilayer as either
pleurocidin or pleurocidin-VA (Fig. 1a, c).
Notably, when the three histidines do not carry a positive
charge, the difference in total peptide to lipid hydrogen bonds is
greatly enhanced (Fig. 1b) indicating that selectivity of
pleurocidin-KR will be diminished. The increase in hydrogen
bonding can be shown to occur almost exclusively via the four
arginine residues (Fig. 1g–i) and the increase in intermolecular
hydrogen bonding occurs at the expense of intramolecular
hydrogen bonding that would otherwise stabilise ordered α-
helix/β-turn conformation (Supplementary Fig. 3).
Pleurocidin analogues have increased conformational flex-
ibility in model membranes. Although pleurocidin adopts a
secondary structure with high α-helix content in many membrane
mimicking environments11,12,18,19, in those that more closely
resemble the plasma membrane of a Gram-negative bacterium,
i.e. rich in a mixture of zwitterionic phosphatidylethanolamine
and anionic phosphatidylglycerol, the structure becomes sub-
stantially, though not completely, disordered11,12. The key
interactions that determine the extent of this conformational
disorder are unknown but, considering the impact of the lipid
environment, are likely to include the sum of peptide–lipid
interactions, notably hydrogen bonding as above but also
hydrophobic effects, Coulombic interactions as well as the order
of the lipid bilayer and the presence/absence of unsaturated acyl
chains.
Both all-atom MD simulations and CD experiments show that
the secondary structure of the two pleurocidin analogues differs
from that of the parent molecule (Fig. 2 and Supplementary
Figs. 3–6). In contrast with our recent, analogous studies of aurein
2.5 and temporin L, where both peptides adopt ordered α-helix
conformations with little flexibility evident beyond the N- and C-
termini20, the present MD simulations reveal pleurocidin and its
analogues exhibit substantial conformational flexibility, as evi-
denced by high circular variance of the psi dihedral angle,
throughout the length of the peptide (Fig. 2b, e, h). The time-
resolved analysis of psi dihedral angles and its circular variance can
be compared with various measures of secondary structure
including n–n+ x hydrogen bonding, Ramachandran plots of
starting and final structures, and both dictionary of secondary
structure of proteins21 and DIhedral-based Segment Identification
and CLassification22 analyses (Supplementary Figs. 3–6). Notably,
while a preference for an extended α-helix conformation can be
detected in pleurocidin in a long segment from Lys8 to Ala21,
when eight peptides are considered (Supplementary Fig. 7), and in
segments between Lys8 and Gly13 and also Ala20-Leu25, when
four peptides are considered (Fig. 2b), this is largely absent from
pleurocidin-KR (Fig. 2e and Supplementary Figs. 7 and 8).
Interestingly, the preference for β-turn conformation (α-helix like)
at the C-terminus is retained and perhaps enhanced in pleurocidin-
VA but α-helix type conformation is lost from all residues
preceding Lys14 (Fig. 2h and Supplementary Figs. 7 and 8).
When the simulations are repeated with histidines carrying no
overall charge, the differences in conformational preference
between the three analogues are retained although the conforma-
tional flexibility of pleurocidin around the segments of α-helix
conformation is notably reduced (Supplementary Fig. 8). The
conformational flexibility of pleurocidin-KR and pleurocidin-VA
is not noticeably affected by the protonation state of the three
histidines. Finally, analogous MD simulations performed with an
anionic, POPG membrane indicate that the membrane composi-
tion influences the conformation of the bound pleurocidin and its
analogues (Supplementary Fig. 9). A preference for α-helix and/or
type I β-turn is now displayed throughout the length of
pleurocidin, a segment with dihedral angles consistent with α-
helix and/or type I β-turn appears between Phe6 and His11 in
pleurocidin-VA, concomitant with an increase in n–n+ 4
hydrogen bonds, but pleurocidin-KR is unaffected and little or
no α-helix conformation detected during the 200 ns of the
duplicate simulations.
These data obtained from MD simulations of the first 200 ns of
peptide binding are qualitatively supported by CD measurements
performed in the steady state (Fig. 2c, f, i). This indicates that,
while all three peptides have a preference for α-helix like
conformation (as observed in SDS), in both POPE/POPG and
POPG models membranes, the conformation of pleurocidin and,
to a greater extent, pleurocidin-KR present spectra consistent
with β-turn conformation (Fig. 2c, f). Pleurocidin-VA also adopts
a β-turn type conformation in POPE/POPG which is greatly
enhanced in POPG (Fig. 2i). The mirror image CD spectra
presented by the all D-amino acid analogues indicate that D-
pleurocidin and D-pleurocidin-KR adopt conformations that are
the mirror image of their all L-counterparts (Supplementary
Fig. 10).
Modifications to the pleurocidin primary sequence funda-
mentally alter activity against model membranes. Having
established that conformation and peptide–lipid hydrogen
bonding is altered in pleurocidin analogues when binding to lipid
bilayers, we then examined the impact of this on bilayer pene-
tration and disruption. In both types of membranes, but most
notably in those modelling the Gram-negative plasma membrane,
pleurocidin-KR inserts more readily and is much more disruptive
than either its parent or the pleurocidin-VA analogue.
Consistent with previous work12, in the 200 ns MD simula-
tions, time-resolved insertion by all three peptides in both bilayers
proceeds predominantly via the more hydrophobic N-terminus,
with some penetration of the bilayer via the C-terminus segment
observed, in particular in the POPG bilayers (Fig. 3a, c, e, g, i, k).
The charge state of the three histidine residues is important for
this process (Supplementary Fig. 11). When the histidines do not
carry a positive charge, pleurocidin and its analogues struggle to
insert into the bilayer as effectively, with penetration in the N-
terminus restricted to the first four residues and the C-terminus
failing to penetrate entirely.
Time-resolved penetration of POPE/POPG (Fig. 3a, e, i) or
POPG (Fig. 3c, g, k) bilayers differed according to peptide and
bilayer composition, however, with POPE/POPG bilayers provid-
ing greater discrimination. In POPG bilayers all three peptides
insert into the hydrophobic core of the bilayer by the end of the
200 ns simulations with N-terminus, central and C-terminus
segments all penetrating below the plane of the lipid phosphates.
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Some qualitative differences are apparent however with
pleurocidin-KR penetrating more than pleurocidin between
Gly13 and Ala19 (Fig. 3c, g) and pleurocidin-VA penetrating
less than pleurocidin between Ala9 and Ala/Val12 (Fig. 3c, k).
Consistent with this, electrophysiology measurements using
the Port-a-patch® automated patch-clamp system of each
analogue challenging 1,2-diphytanoyl-sn-glycero-3-phospho-(1′-
rac-glycerol) (DPhPG) bilayers (Fig. 3d, h, l) indicate all three
peptides induce ion conductance activity at comparable peptide
concentrations. Again, some qualitative differences are apparent;
while all three peptides generate a mix of irregular but also
channel like activities, the latter was consistently observed more
frequently for pleurocidin-KR. Pleurocidin and, in particular
pleurocidin-VA, were consistently more likely to trigger bursts of
conductance of varying amplitude which lacked discrete opening
levels.
The interaction of pleurocidin and its two analogues with
POPE/POPG bilayers differs substantially. In MD simulations,
much greater penetration of the hydrophobic core was observed
between Lys/Arg7 and His15—the region where hydrogen
bonding is enhanced by three of the four lysine to arginine
substitutions—for pleurocidin-KR over pleurocidin (Fig. 3a, e).
Insertion by pleurocidin-VA is more like that of pleurocidin but
penetration of Lys14/His15 is weaker and more reliant on Phe5/
Phe6 at the N-terminus. Disordering of the lipid acyl chains was
also monitored in the MD simulations (Fig. 3o, p and
Supplementary Fig. 12) as well as by 2H solid-state NMR of
chain deuterated POPG (Fig. 3m) or POPE (Fig. 3n). In MD
simulations, AMPs have been shown to disorder lipids that are
close to the peptide while those that are more distant become
more ordered23,24. Such data, from the first 200 ns of a
peptide–bilayer interaction, will not perfectly correlate with 2H
NMR data obtained in the steady state. Nevertheless, both
methods indicate pleurocidin-KR induces greater disorder than
pleurocidin or pleurocidin-VA although manifested in the
zwitterionic POPE component in the MD simulations and in
the anionic POPG component by NMR (Fig. 3o, m). Electro-
physiology measurements reveal both lysine to arginine and
valine to alanine substitutions fundamentally alter membrane
activity in 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine
(DPhPE)/DPhPG models of the Gram-negative plasma mem-
brane. Challenge with pleurocidin induces irregular and high
intensity activity, with no evidence of channel like activity, that
gradually subsides with the bilayer remaining intact (Fig. 3b).



































































































Fig. 2 Secondary structure analysis of pleurocidin peptides. Top view snapshots showing ordered/disordered conformation for each of eight peptide
monomers (a, d, g) binding to POPE/POPG bilayers in silico. From the same simulations, average psi dihedral angles and circular variance of psi are shown
for each residue, averaged over 200 ns of simulation and eight peptides (b, e, h). Far-UV CD spectra obtained in anionic SDS detergent micelles or models
of Gram-negative or Gram-positive plasma membranes comprising, respectively, POPE/POPG or POPG lipids (c, f, i). Data are shown for pleurocidin (a–c),
pleurocidin-KR (d–f) and pleurocidin-VA (g–i).
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This is consistent with pleurocidin inducing conductance as it
passes from one leaflet of the bilayer to the other and with its
known ability to penetrate within bacteria as part of its
bactericidal activity. In contrast, challenge with pleurocidin-KR
reproducibly leads to a gradual increase in, again, irregular
conductance, until the bilayer breaks (Fig. 3f). Conductance in the
DPhPE/DPhPG membrane induced by pleurocidin-VA was
inconsistent. Frequently very high peptide concentrations are
required to trigger activity and often no activity is detected at all.
When activity is observed it is irregular and with high intensity
(Fig. 3j).
Pleurocidin analogues offer species and environmental
dependent improvements in antibacterial potency, broadening
the spectrum of activity. Next we investigated whether there is
evidence for the altered mechanism of action altering anti-
bacterial activity, first through assessing potency in vitro against a
panel of Gram-negative or Gram-positive pathogens using the
AMPs either alone (Table 2) or in combination with clinically
relevant antibiotics (Supplementary Table 2) and, second,
through an NMR metabolomic study of how bacteria respond to
challenge with the all D-amino acid pleurocidin and its -KR or
-VA analogues. Antibacterial susceptibility testing was conducted
both in Mueller Hinton Broth (MHB), as recommended25, and
also in Roswell Park Memorial Institute 1640 (RPMI) medium.
The latter was used since recent studies have shown that both
false-negative26 and false-positive27 results can arise from exclu-
sively testing antibiotic susceptibility in MHB alone.
In MHB, pleurocidin possesses broad spectrum activity. However,
with the notable exception of Pseudomonas aeruginosa, activity
against Gram-negative isolates is generally higher than that against
Gram-positive isolates. The potency of pleurocidin-KR is marginally
greater than that of pleurocidin against most Gram-negative isolates
but against P. aeruginosa and Gram-positive isolates, the improve-
ment is more substantial. The potency of pleurocidin-VA is
comparable to the parent peptide against Gram-negative isolates
but reduced against Gram-positive isolates. Most notably however,
the in vitro cytotoxicity of pleurocidin-VA against four mammalian
cell lines is severely attenuated (Table 2). Analogues composed
entirely of D-amino acids do not gain antibacterial potency over their
all L-amino acid enantiomers in MHB, suggesting there is little to no
difference in their mechanism of action.











 POPE:POPEd31:POPG + 2 mol% pleurocidin
 POPE:POPEd31:POPG + 2 mol% pleurocidin VA























































































































































































































 POPE:POPGd31 + 2 mol% pleurocidin
 POPE:POPGd31 + 2 mol% pleurocidin VA
 POPE:POPGd31 + 2 mol% pleurocidin KR
Fig. 3 Activity of pleurocidin and its analogues on in silico and in vitro models of bacterial plasma membranes. The depth of insertion into each
membrane is shown as the Z-position for each residue, averaged over all four peptides, relative to the phosphate group plane in the upper POPE/POPG
(a, e, i) or POPG (c, g, k) bilayer leaflet in six MD simulations. Positive or negative values indicate the peptides are below or above the phosphate group.
Representative current traces illustrating membrane activity when DPhPE/DPhPG (b, f, j) or DPhPG (d, h, l) model membranes are challenged with each
peptide at the lowest concentration that induced detectable activity. Data are for pleurocidin (a–d), pleurocidin-KR (e–h) and pleurocidin-VA (i–l).
Membrane disordering by each peptide in mixed POPE/POPG bilayers is shown with data obtained from 2H solid-state NMR (m, n) or from MD
simulations where order parameters are calculated for all lipids within 4 Å of a peptide (o, p).
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None of the analogues, whether comprising L- or D-amino
acids demonstrate noticeable haemolysis at the concentrations
where they are effective antibacterials (Supplementary Fig. 13)
and the in vitro therapeutic index over red blood cell haemolysis
for the majority of isolates ranges between 18- and 150-fold for D-
pleurocidin-KR (10% haemolysis achieved with ~75 µg/ml).
Performing the same experiments with RPMI, supplemented
with 5% fetal bovine serum (FBS), in place of MHB alters the
susceptibility pattern considerably with Gram-negative and
Gram-positive isolates affected differently and greater discrimi-
nation between L- and D-enantiomers and the greater proteolytic
stability of the D-enantiomer is likely now important28. Although
Gram-negative isolates are generally less susceptible in RPMI
when compared with MHB, the D-enantiomers better retain their
activity, with D-pleurocidin-KR notably remaining effective at 4
µg/ml or less for all but the P. aeruginosa isolates. In contrast, the
potency of the pleurocidin analogues in RPMI is most commonly
enhanced against Gram-positive isolates, when compared with
MHB, with D-enantiomers now gaining an advantage. This
improvement is most noticeable for D-pleurocidin such that its
disadvantage with respect to D-pleurocidin-KR, in these condi-
tions, is negligible. Nevertheless, the selectivity index over
epithelial cells reveals D-pleurocidin-KR as the analogue with
the greatest therapeutic potential for EMRSA-15, an isolate for
which a murine lung infection model has been established in our
laboratory.
Testing of combinations of D-pleurocidin or D-pleurocidin-KR
with clinically useful antibiotics was also assessed in vitro in both
MHB and RPMI (Supplementary Table 2). Both peptides act in
modest synergy with the aminoglycoside tobramycin or with
rifampin. This effect was most noticeable when P. aeruginosa
RP73 was tested in RPMI and the same bactericidal activity is
achieved with eight times less tobramycin or rifampin as is
achieved without the peptide adjuvant.
While the ability of pleurocidin both to damage bacterial
plasma membranes and penetrate within bacteria to access
intracellular targets is established, the relative contributions of
these properties to its bactericidal activity against different
bacterial species may vary and may also be influenced by growth
conditions. Assays with fluorescent reporter dyes have revealed
that hydroxyl radical increases and membrane permeabilization
following challenge with pleurocidin at its MIC vary substan-
tially29. Killing of Escherichia coli ATCC 25922 or S. aureus
ATCC 25923 involved substantial oxidative stress but little
membrane permeabilization. In contrast, much more permeabi-
lization of P. aeruginosa ATCC 27853 and Enterococcus faecium
ATCC 19434 was induced by pleurocidin, in addition to oxidative
stress. To test whether the mechanisms of action distinct from
that of D-pleurocidin are adopted by its analogues and to better
understand the role of bacterial metabolism in susceptibility, we
performed an NMR metabolomic study (Fig. 4 and Supplemen-
tary Figs. 14–29). By culturing either EMRSA-15 or P. aeruginosa
RP73 in the presence or absence of each D-pleurocidin analogue,
we aim to infer differences in their bactericidal strategy from the
measures the bacteria take to overcome the challenge.
In MHB, as monitored by 1H NMR, EMRSA-15 metabolism is
a mix of fermentation, aerobic and anaerobic respiration. The
production of formate, lactate and ethanol indicate threonine,
serine and glycine and what little glucose is present mostly feed
mixed-acid fermentative pathways, consistent with acidification of
the spent media (Fig. 4a and Supplementary Figs. 14 and 16)30,31.
Uridine consumption and uracil production are associated with
peptidoglycan biosynthesis while uracil is known to be essential
for anaerobic growth30,32. Succinate excretion to the media is
consistent with anaerobic respiration, with fumarate acting as an
electron acceptor.
The effect on this process, of challenging EMRSA-15 with sub-
inhibitory D-pleurocidin, is profound (Supplementary Fig. 16)
and results in both a fundamental change in metabolic strategy
and in cellular metabolite composition (Fig. 4g and Supplemen-
tary Fig. 17). Fermentation of serine, glycine and glucose, but not
threonine, is stopped following challenge with D-pleurocidin and
the acidification of the spent culture is reduced (Supplementary
Fig. 14). Excretion of ornithine, succinate, ethanol, lactate,
leucine, methionine and 2-aminobutyrate consequently halts
while consumption of uridine is also stopped. Consumption of
adenosine, acetate and aspartate increases while the challenge
initiates consumption of lysine, arginine, tyrosine, and valine.
Lysine and valine feed into the TCA cycle via, respectively, α-
ketoglutarate and succinyl-CoA. Consumption of glutamate and
isoleucine from the media is reversed and these amino acids are
instead excreted while formate and phenylalanine are consumed
instead of being excreted. Within the cell, succinate and uracil are
depleted, as are choline, citrulline and valine while acetate and
betaine increase. Consumption of tyrosine and phenylalanine (via
the homogentisate pathway described for Pseudomonas putida33)
and aspartate can all be associated with the production of
fumarate. Therefore, both fumarate and nitrate might be expected
to be important anaerobic electron acceptors30. However, the halt
of succinate excretion and its intracellular depletion points to a
potential switch from fumarate to nitrate as an anaerobic electron
acceptor. The concentration of the latter in MHB is unknown and
is invisible to the NMR method, but 2′-7′dichlorodihydrofluor-
escin diacetate (DCFH-DA) fluorescence, which is sensitive to
reactive oxygen species and reactive nitrogen species, increases on
challenge with D-pleurocidin (p= 0.044) but not the other
analogues (Fig. 4d). Taken together, EMRSA-15 growing in the
presence of D-pleurocidin is unable to use fermentation and
instead relies more heavily on anaerobic respiration, while the
TCA cycle is active but fed from new carbon sources.
The effects of both D-pleurocidin analogues on EMRSA-15 can
be distinguished from the parent peptide (Fig. 4d, h, i). Unlike D-
pleurocidin, neither D-pleurocidin-KR nor D-pleurocidin-VA
affect fermentation to any great extent (Fig. 4h, i and
Supplementary Fig. 16). D-pleurocidin-KR and D-pleurocidin-
VA can be distinguished based on increased acetate consumption
and alanine, glutamate and histidine excretion for the latter. The
response of the cellular metabolite composition is more revealing,
with the D-pleurocidin-VA treatment resembling more closely the
effect of D-pleurocidin challenge on EMRSA-15 (Fig. 4j, l).
Following challenge with sub-inhibitory D-pleurocidin-KR, eight
times more potent than D-pleurocidin in MHB, there is no
depletion of choline, citrulline or valine, that of succinate is
mitigated and uracil is instead increased. The levels of acetate and
betaine are as that observed for the unchallenged condition, but
aspartate is depleted, and lactate, leucine and isoleucine levels are
increased alongside plasma membrane lipid unsaturation (Fig. 4g
and Supplementary Fig. 17). The mechanism of action of the
more potent D-pleurocidin-KR, as inferred from changes in
EMRSA-15 metabolism, is therefore fundamentally different from
that of the parent D-pleurocidin in MHB and may depend on a
greater contribution from membrane damage.
In glucose-rich RPMI, while ethanol is still produced, the
fermentative production of lactate by EMRSA-15 is much more
substantial such that the media is acidified still further, potentially
triggering stress (Fig. 4b and Supplementary Fig. 14), and little or
no formate is produced. Both fermentation and anaerobic
respiration may again be expected with RPMI containing 2 g/
litre glucose and 100 mg/litre calcium nitrate as a potential
electron acceptor. As well as glucose, notably 300 mg/litre
glutamine is available, and its consumption is also preferred
(Fig. 4b). This might ensure that the TCA cycle is being fed via 2-
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oxoglutarate but may also reflect the roles of glutamine as a major
nitrogen donor, in osmotic protection and in multiple steps of
peptidoglycan synthesis34,35. The effect of this change in
metabolic strategy for the cellular metabolite composition is
substantial (Fig. 4c) and may render the bacteria more susceptible
to the action of D-pleurocidin and its analogues. In contrast with
their effect in MHB, apart from a halt in proline and histidine
excretion, the three analogues have only a modest impact on the
metabolism of EMRSA-15 in RPMI (Supplementary Fig. 19).
Although there is a trend towards an increase in DCFH-DA
fluorescence on challenge with D-pleurocidin (Fig. 4e), overall the
response is similar for all three peptides and, critically, glucose
consumption and lactate and ethanol excretion are largely
unaffected. The impact of the three analogues on the cellular
metabolite composition is similar (Supplementary Fig. 20). As
observed for D-pleurocidin challenge of EMRSA-15 MHB above,
succinate, uracil and adenosine are depleted, and cellular acetate
increases following challenge with all three analogues. Reflecting
the similarity in their MIC in RPMI, apart from a modest increase
in plasma membrane lipid unsaturation and a depletion of 2-
aminobutyrate and lysine, there is therefore much less to
distinguish the action of D-pleurocidin-KR from its parent.
A similar study was performed for P. aeruginosa RP73. There is
little evidence of fermentation for P. aeruginosa RP73 when
cultured in MHB or RPMI, where there is notable consumption
of, respectively, formate and lactate. This strain was isolated from
a cystic fibrosis patient where consumption of lactate is
characteristic36. Lactate is a substrate for a family of lactate
dehydrogenases which support anaerobic or aerobic metabolism
and is present in the added FBS which is essential for growth of P.
aeruginosa in RPMI36. In both media therefore a more substantial
role for anaerobic respiration is expected, albeit supported by
differing electron donor and acceptor pairs. Consequently, while
an increase in DCFH-DA fluorescence is again detected on D-
pleurocidin challenge of P. aeruginosa RP73 in MHB and modest
changes in metabolite consumption are detected, there is no
accompanying fundamental shift in metabolic strategy (Supple-
mentary Fig. 22). Indeed, no fundamental change in metabolism
is induced by challenge with either D-pleurocidin or D-
pleurocidin-KR or tobramycin. In RPMI, challenge with sub-
inhibitory concentrations of D-pleurocidin-KR, but not D-
pleurocidin, induces a substantial increase in DCFH-DA
fluorescence emission and also in the intensity of resonances
assigned to lipid-CH3, lipid-CH2 and lipid –CH= CH– while
there are key differences in the metabolic perturbations it induces;
most notably, isoleucine, leucine, methionine, phenylalanine,
tyrosine and valine are all consumed less, relative to D-pleurocidin
challenge, while arginine consumption continues and may
increase, excretion of acetate substantially decreases while that
of aspartate, glutamate and ornithine continues and may increase
and, lysine excretion is triggered (Supplementary Figs. 23 and 27).
A similar but more muted trend in membrane remodelling is
observed for P. aeruginosa RP73 challenged in MHB (Supple-
mentary Figs. 23 and 25). From these data, it may again be
inferred that the impact of D-pleurocidin-KR is felt more keenly
at the plasma membrane when compared with its D-pleurocidin
parent. For P. aeruginosa RP73 however, while differences in
response to the two D-pleurocidin analogues can be detected,
which again suggest they operate using distinct mechanisms, the
effect on antibacterial potency is minor.
D-pleurocidin-KR is an effective therapeutic in a murine model
of EMRSA-15 lung infection. Having identified that the
enhanced membrane disrupting capabilities of D-pleurocidin-KR
renders it less sensitive to infection setting dependent changes in
bacterial metabolism and since the selectivity index for inhibition
of EMRSA-15 relative to HEK293 cellular toxicity was greatest for
D-pleurocidin-KR of all the analogues tested, we advanced D-
pleurocidin-KR to an established murine model of EMRSA-15
infection (Fig. 5).
D-pleurocidin-KR is readily soluble in aqueous media and
amenable to intravenous delivery. A dose of 1 × 106 colony
forming units (CFU)/mouse of EMRSA-15 in tryptic soy agar
beads inoculated in the lung establishes a stable infection (4.26 ±
0.24 log10 CFU/ml at 4 h; 4.43 ± 0.97 log10 CFU/ml at 48 h)
which, if untreated, causes approximately a 5% loss of weight in
48 h (Fig. 5b). Treatment with a cumulative dose of 15 or even
1.5 mg/kg/48 h D-pleurocidin-KR mitigates this weight loss to a
similar extent to that achieved with 600 mg/kg vancomycin (a
similar reduction may be achieved in this model with lower doses,
c.f. 200 mg/kg vancomycin i.p. gives a comparable reduction in S.
aureus USA300 CFU37), although the lowest dose of 0.15 mg/kg
D-pleurocidin-KR has no observable effect (Fig. 5b). The two
higher doses also achieve a significant reduction in CFU with 1.1
and 0.9 log10 reduction achieved, respectively, for 15 and 1.5 mg/
kg/48 h doses, comparable with that achieved with vancomycin
(Fig. 5a). Since D-pleurocidin-KR was tolerated at 15 mg/kg/24 h
when administered i.v., its in vivo therapeutic index is ~20-fold,
before dose optimisation.
The effect of D-pleurocidin-KR therapy on the innate immune
response was also characterised through analysis of bronchoal-
veolar lavage fluid (BAL) (Fig. 5c–i). The mouse keratinocyte
chemoattractant (KC), equivalent to CXCL1 in humans, response
is similar to that observed for lung CFU with infection
stimulating an increase in this cytokine and treatment with
vancomycin or the two higher D-pleurocidin-KR doses causing
KC levels to fall to that of the uninfected group (Fig. 5h). Both IL-
6 and neutrophil recruitment (reflected also in total cell numbers;
Fig. 5c) are reduced following therapy with either vancomycin or
D-pleurocidin-KR. However, a significant reduction is also
observed for the lowest dose of D-pleurocidin-KR (Fig. 5d, f),
which did not cause a significant reduction in lung CFU or mouse
KC. No effects of vancomycin and D-pleurocidin-KR therapy
could be detected on macrophage numbers or levels of TNFα or
MCP-1 in BAL (Fig. 5e, g, i). Mouse KC is sensitive to EMRSA-15
lung infection while IL-6 reflects neutrophil recruitment and
these data indicate D-pleurocidin-KR effectively reduces the
burden of lung infection and may have a dampening effect on
neutrophil recruitment but we do not observe evidence of a
substantial innate immune response.
Discussion
A list of 27 clinical and 9 pre-clinical studies of AMPs, published
in May 2019, shows there is considerable appetite for developing
Fig. 4 NMR metabolomics identifies altered mechanism of action in D-pleurocidin analogues. Volcano plots obtained from liquid state 1H NMR of spent
bacterial culture reveal the metabolic strategy of EMRSA-15 in MHB (a), challenged with D-pleurocidin (g), D-pleurocidin-KR (h) or D-pleurocidin-VA (i), or
in RPMI (b). Tentative assignments are indicated by (t). The major catabolic pathways of EMRSA-15 are shown for context with key enzymes: FDH formate
dehydrogenase, SDH succinate dehydrogenase, NR nitrate reductase, NiR nitrite reductase (f). 1H HR-MAS NMR of bacterial pellets reveals the effect on
cellular metabolites of growth in these media (c) or challenge with antibiotics in MHB (j–l). Production of ROS/RNS when challenged by antibiotics, as
monitored by DCFH-DA, is shown for MHB (d) and RPMI (e). Data points are averages from six distinct colonies. Boxes represent 1 SE and whiskers 1.5 SE
of three independent repeats. Significance is relative to the D-pleurocidin challenge (*p < 0.05; **p < 0.01).
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peptide-based molecules as potential therapeutics38. Of these 36
AMPs however, only 7 are/were being developed for intravenous
delivery. Of these seven, three have been discontinued and three
(EA-230, Ghrelin and p2TA (AB103)) function via immunomo-
dulation. Only one, hFF1-11, a lactoferricin derivative has shown
direct antimicrobial activity through membrane disruption but
the in vivo efficacy may also be related more to its immunomo-
dulatory capabilities which include the release of pro-
inflammatory cytokines and stimulation of monocyte differ-
entiation39–41. As a result, with few if any bactericidal AMPs
finding i.v. applications, a recent, authoritative review has
expressed the opinion that “AMPs may never be able to achieve
the same clinical outcomes as conventional antibiotics” with
neither naturally occurring nor rationally designed AMPs suffi-
ciently potent42. Helpfully, Haney et al identify key areas where
improved understanding may nevertheless contribute to more
fruitful translation of AMPs into useful therapeutic agents. These
include: (1) the perception that each individual amino acid resi-
due may have an important role and that no single active
conformation exists; (2) specific to AMPs that access the bacterial
cytoplasm, better models of bacterial plasma membrane translo-
cation concomitant with, or in the absence of, permeabilization;
(3) determining what features of a given infection setting are
reproduced by each in vitro assay and; (4) the concept that
exogenous AMPs are unlikely to act in isolation and may act in
synergy with the host innate immune system (and also clinically
relevant antibiotics).
We have shown that analogues of pleurocidin, in particular D-
pleurocidin-KR, are potent bactericidal AMPs which can be
delivered intravenously to treat bacterial lung infections without
triggering the release of pro-inflammatory cytokines or stimu-
lating recruitment of innate immune cells in the mouse model.
The modification strategy ensures that in some cases a 16-fold
improvement in potency is observed for D-pleurocidin-KR over
pleurocidin and this compares favourably with e.g. efforts to
obtain shortened pleurocidin analogues43,44. Furthermore, the
bactericidal activity of pleurocidin can be rendered less sensitive
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Fig. 5 Systemically delivered D-pleurocidin-KR is effective in a murine model of EMRSA-15 lung infection. C57Bl6J mice, challenged with 1 × 106 CFU/
mouse EMRSA-15 in tryptic soy agar beads, were treated with vancomycin or D-pleurocidin-KR in three intravenous doses at 4, 24 and 30 h post infection
to achieve the cumulative doses indicated. Bacterial burden in the lung (a), weight loss over the 48-h infection period (b) and BAL cells (c–e) and cytokines
(f–i) reveal the effect of each intervention. Data presented are an aggregate of two independent repeats, each with control groups (n= 6) and peptide
treatment groups (n= 4). Significance is indicated relative to the saline vehicle (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). Bars represent mean
and SEM.
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interaction with lipid bilayers; even relatively minor modifications
are sufficient to ensure an altered mechanism of action. Both D-
pleurocidin and the D-pleurocidin-KR analogue can act in
synergy with the aminoglycoside tobramycin or rifampin in vitro
and there is therefore some promise that AMPs may find appli-
cation as adjuvants to existing, clinically relevant antibiotics. This
may be achieved in particular by reducing the risk of resistance
emerging, either via manipulation of seesaw mechanisms45 or
through an improved pharmacodynamics profile46.
The MD simulation and patch-clamp studies, using bacterial
plasma membrane models, offer a mutually supporting view of
the variety of ways that pleurocidin AMPs may interact with the
plasma membrane of differing bacteria. In the context that
pleurocidin is known to both disrupt the bacterial plasma
membrane but also translocates to seek intracellular targets6,9,10,
observations from patch-clamp studies identify membrane
activity consistent with both of these properties. The highly
irregular but high amplitude conductance that diminishes over
time, observed for pleurocidin most notably in membranes that
model the Gram-negative bacterial plasma membrane and remain
intact, is consistent with an AMP crossing the bilayer without
major structural disruption. Such activity is also observed in
models of Gram-positive plasma membranes where, additionally,
more channel like conductance is observed. Taken together with
previous fluorescence studies that reveal species and even strain
dependent differences in the extent of membrane permeabiliza-
tion caused by pleurocidin at its minimum inhibitory con-
centration29, this suggests that a primary mechanism of action
will be to penetrate the bacteria but at higher concentrations a
secondary, membrane disruptive, effect will be observed. While
differences between bacterial species and strains, and also their
environment will impact on which of these two effects contributes
most to bacterial death, it is shown here that the interaction
between peptide and lipid bilayer can be manipulated to increase
the role of membrane damage in the bactericidal strategy.
Notably, the MD simulations, supported by CD spectroscopy,
show increasing hydrogen bonding between the bilayer and the
peptide produces much greater conformational flexibility and
consequently disordering of the bilayer. This highlights the
importance of peptide–lipid hydrogen bonding in modulating the
interaction of pleurocidin with bilayers of differing composition
and shows how this, and the charge state of the three histidines, is
critical in determining the outcome. Positively charged histidines
enjoy favourable Coulombic interactions with anionic lipids
which will also mitigate unfavourable interactions between his-
tidines and lysines that might be positioned close in space, thus
affecting not only binding to surfaces of varying anionic charge
but also modulating the preferred conformation. Further, the
hydrogen bonding potential of positively charged histidine is
greater. This, together with varying possibilities for hydrogen
bonding for lipids common in prokaryotic (phosphatidylglycerol
and phosphatidylethanolamine—a primary amine) and eukar-
yotic (phosphatidylcholine—a quaternary amine—is more com-
mon) plasma membranes, highlights the role of histidine as a
selectivity switch, influencing the likely therapeutic index of these
compounds. In the absence of histidine mediated hydrogen
bonding, the interaction of pleurocidin-VA with less anionic
bilayers is much weaker than that of the parent in the centre and
C-terminal segments. Further manipulation of this property may
offer additional means of improving selectivity.
The distinct mechanisms of action of D-pleurocidin and D-
pleurocidin-KR highlight two aspects of AMP development that
may be important in successful translation. If it is possible to
fundamentally alter the mechanism of action within members of
a structure–activity relationship series with only a few amino acid
substitutions, then it is likely that exogenous AMPs will differ in
mechanism from endogenous host defence peptides (HDPs),
making additive relationships less likely. Further, although exo-
genous AMPs may share some characteristics with endogenous
HDPs, it can be expected that the extent of cross resistance will be
mitigated by significant differences in mechanism of action.
There is increasing recognition that susceptibility testing in
bacteriological media may both under- or over-estimate the
potency of different classes of antibiotics and is unlikely to
replicate the conditions encountered in vivo26,27. In spite of well-
established protocols for susceptibility testing of antibiotics,
including AMPs25, the methodology used to determine anti-
bacterial potency of AMPs remains highly variable42. The use of
mammalian cell culture media has been presented as a move
towards better replicating the infection setting and presents
AMPs with some notable challenges including increased ionic
strength and the presence of serum proteases. Altered growth
conditions may also affect the production of virulence
factors47,48. The D-enantiomers of pleurocidin and its analogues
did not outperform their L-amino acid parent molecules until
RPMI (5% FBS) was used in place of MHB. The need to modify
linear AMPs to avoid proteolytic degradation in more challenging
conditions is therefore clear.
While mammalian cell culture media may present greater
challenges to AMPs, and this is notable in their activities against
Gram-negative isolates, bacterial metabolic activity may also
affect antibiotic outcomes49 and it is of considerable interest that,
irrespective of stereochemistry, pleurocidin analogues are more
potent against many of the Gram-positive isolates than their
parent molecules. Further, the difference in potency between D-
pleurocidin and D-pleurocidin-KR against EMRSA-15 disappears
when susceptibility testing is performed in RPMI with both
peptides more potent than when evaluated in MHB. EMRSA-15
growth in MHB adapts to the presence of D-pleurocidin by
shutting down fermentation and placing greater reliance on
anaerobic respiration, most likely using nitrate as an electron
acceptor. This response is not observed when EMRSA-15 is
challenged with the more potent D-pleurocidin-KR. This can be
attributed to the lower concentration of D-pleurocidin necessarily
used for the challenge and/or a fundamentally altered mechanism
of action. The latter is supported by evidence that EMRSA-15
responds to D-pleurocidin-KR, which carries substitutions which
cause greater disruption of model bilayers, by remodelling its
plasma membrane. While it is not clear whether the gain in
membrane disruption in D-pleurocidin-KR occurs at the expense
of the ability to penetrate the bacterial cytosol, this property
appears crucial in reducing sensitivity to the bacterial metabolic
strategy. The increased dependence on fermentation can be
implicated in rendering EMRSA-15 more sensitive to the action
of D-pleurocidin analogues. While the origin of their increased
potency against EMRSA-15 in RPMI (5% FBS) is not completely
clear, it is nonetheless welcome and suggests that, if EMRSA-15
adopts a fermentative metabolic strategy in a lung infection set-
ting then, all D-pleurocidin analogues will be more potent than
anticipated and there is little advantage to selecting D-
pleurocidin-KR. However, although mammalian cell culture
conditions have been suggested as a better means of reproducing
the bacterial metabolic strategy in vivo26,27, infection setting
dependent variation in nutrient availability can be expected to
affect therapeutic outcomes31. Indeed, although fermentable
substrates, including glucose are abundant in the lung infection
setting, a recent study of S. aureus gene expression during cystic
fibrosis lung infections finds that expression of genes involved in
fermentation and use of nitrate as an electron acceptor is low48.
This would then predict a greater chance of therapeutic success
for D-pleurocidin-KR over D-pleurocidin. The varying sensitivity
of the D-pleurocidin analogues to bacterial metabolism highlights
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again the importance of efforts to improve our understanding of
bacterial metabolism in different infection settings48,50. The
present study, however, suggests that including a range of con-
ditions in in vitro susceptibility testing, that stimulate different
metabolic strategies in target bacteria, may be important in
selecting AMPs that are resilient and improving success of AMPs
in pre-clinical studies.
The immunomodulatory abilities of HDPs are increasingly
recognised as being critical to their role in the innate immune
system. HDPs have been shown to be capable of inducing or
modifying the production of cytokines or chemokines as well as
inhibiting pro-inflammatory responses from host cells which
might arise from bacterial components including lipoteichoic
acid, peptidoglycan, lipopolysaccharide and bacterial DNA51.
This has led to the design of small synthetic peptides, focusing on
enhancing their immunomodulatory capability52, or enhancing
the immunomodulatory capability of bactericidal peptides iden-
tified in nature53. Analysis of BAL fluid shows no evidence of any
increased cytokine response or recruitment of either neutrophils
or macrophage following i.v. D-pleurocidin-KR administration at
doses that effectively reduce EMRSA-15 load in the lung. The
dampening of IL-6 levels and neutrophil recruitment without any
significant reduction in lung CFU does suggest that D-
pleurocidin-KR can inhibit pro-inflammatory responses either
directly or indirectly. However, since D-pleurocidin-KR is a highly
potent (in vitro MIC 0.5 µg/ml/0.18 µM), bactericidal AMP
against EMRSA-15 and, with no evidence of an immune-
stimulatory effect in vivo, its therapeutic effect must currently
also be primarily ascribed to a direct effect on bacteria at the site
of infection.
With appropriate modification and an understanding of the
requirements for bactericidal activity that is robust in the face of
different bacterial metabolism and more challenging environ-
mental conditions, pleurocidin analogues are effective in treating
an EMRSA-15 lung infection. Although pleurocidin may repre-
sent a special case, our results suggest that, despite widely held
concerns, bactericidal AMPs may yet be suitable for development
for intravenous delivery and systemic therapeutic applications.
Methods
Peptides and lipids. Pleurocidin, pleurocidin-KR, pleurocidin-VA and their all D-
amino acid analogues were purchased from Cambridge Research Biochemicals
(Cleveland, UK) as desalted grade (crude). The crude peptides were further purified
using water/acetonitrile gradients using a Waters SymmetryPrep C8, 7 mm, 19 ×
300 mm column. All peptides were amidated at the C-terminus. The lipids POPG,
1-palmitoyld31-2-oleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (POPG-d31),
POPE, 1-palmitoyld31-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE-d31),
DPhPG and DPhPE were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL)
and used without any purification. All other reagents were used as analytical grade
or better. Bacterial isolates are from a collection maintained by PHE (for anti-
biogram see Supplementary Table 3).
Antibacterial activity assay. The antibacterial activity of the peptides was
assessed through a modified twofold broth microdilution assay with modal MICs
generated from at least three biological replicate experiments20,25. The method
broadly followed EUCAST methodology, with non-cation-adjusted Mueller Hinton
or RPMI replacing cation-adjusted Mueller Hinton. Peptides and antibiotics were
diluted in a twofold dilution in media down a 96 well plate. Bacteria were then
added, back-diluted from an overnight culture, at a starting concentration of 5 ×
105 CFU/ml. Plates were incubated, static at 37 C, for 20 h and the OD600 was
determined using a Clariostar plate reader (BMG Labtech). The MIC was defined
as the lowest concentration where growth was <0.1 above the background absor-
bance. Synergy was measured using standard microdilution checkerboard assays
under the same conditions as the MICs54. Twofold dilution series of each peptide
or antibiotic were prepared in separate 96 well plates and then combined into one
before addition of bacteria. The growth/no growth interface was determined using
the same definition as the MIC. The fractional inhibitory concentration was cal-
culated from the most synergistic well on the plate for three independent repeats,
and presented as the average +/− standard deviation. FIC is calculated as (MIC of
compound A in combination with B/MIC of compound A alone)+ (MIC of
compound B in combination with A/MIC of compound B alone). MICs were
determined on the same plates as the FICs to increase reproducibility. FIC values
≤0.5 were considered strongly synergistic and, consistent with a recent re-
evaluation of FIC which stresses the importance of also measuring the MIC in the
same microarray plate, values of 0.5 - <1 were weakly synergistic54.
Cytotoxicity assay. HeLa and HEK293 cell lines were purchased from ECACC
and cultured in Eagle’s Minimum Essential Media containing glutamine, supple-
mented with 10% FBS and 1X non-essential amino acids. A549 and Calu-3 cell
lines were purchased from ATCC. A549 cells were cultured in Dulbecco’s Modified
Eagle Medium (DMEM) while Calu-3 cells were cultured in DMEM/F-12, both
supplemented with 10% FBS and 1% antibiotic-antimycotic. All cells were main-
tained at 5–10% CO2, 37 °C. Cytotoxicity was measured by incubating starter
cultures of cells for 24 h in a 96 well plate, gently removing the supernatant and
replacing it with dilutions of peptides and controls, incubating for a further 24 h
and then staining of the cells with the second-generation tetrazolium dye, XTT.
Cells were stained with 0.2–0.3 mg/ml XTT labelling mixture with 5 mM N-methyl
dibenzopyrazine methyl sulfate, subsequently incubated for 4 h and the IC50 was
calculated from the OD475 which was measured using a Clariostar plate reader.
Data presented are averages and standard error from three biological replicate
experiments.
Haemolysis assay. Haemolysis was tested by incubating titrations of AMPs in PBS
with freshly collected human red blood cells for 1 h at 37 °C. Control wells were
treated with 0.1% Triton-X-100 to ensure complete lysis, or PBS-only to represent
no lysis. Samples were spun down to remove non-lysed cells and the OD550 of the
supernatant was measured using a Clariostar plate reader. The percentage of
haemolysis was calculated as % haemolysis= (AP−AB)/(AC−AB) × 100, where
AP is the absorbance value for a known peptide concentration, AC is the absor-
bance of the 0.1% Triton-X-100 control, AB is the absorbance of the PBS control.
Data presented are averages and standard error from three biological replicate
experiments.
NMR structure determination. The NMR samples consisted of a 0.5 mM peptide
solution also containing 50 mM deuterated sodium dodecyl sulphate (SDS-d25)
with 5 mM Tris(hydroxymethyl-d3)-amino-d2-methane buffer at pH 7. 10% D2O
containing trimethylsilyl propanoic acid (TSP) was added for the lock signal and as
internal chemical shift reference. The temperature was kept constant at 310 K
during the NMR experiments. NMR spectra were acquired on a Bruker Avance
800MHz spectrometer (Bruker, Coventry, UK) equipped with a cryoprobe. Stan-
dard Bruker TOCSY and NOESY pulse sequences were used, with water sup-
pression using a WATERGATE 3–9–19 sequence with gradients (mlevgpph19 and
noesygpph19). The 1H 90º pulse was calibrated at 37.04 kHz. The TOCSY mixing
time was 90 ms, and the mixing time for the NOESY spectra was set to 150 ms. The
relaxation delay was 1 s. 2048 data points were recorded in the direct dimension,
and either 256 or 512 data points in the indirect dimension. The spectra were
processed using Bruker TOPSPIN. The free induction decay was multiplied by a
shifted-sine2 window function. After Fourier transformation, the spectra were
phase corrected, a baseline correction was applied, and spectra were calibrated to
the TSP signal at 0 ppm.
CARA55 (version 1.9.1.2) and Dynamo (http://spin.niddk.nih.gov/NMRPipe/
dynamo) software were used for assignments and structure calculation. Inter-
proton NOEs interactions were used as distance restraints in the structure
calculation. After seven iterations using the simulated annealing protocol, CARA
software generated a total of 200 structures on UNIO’08 (version 1.0.4)56 and
XPLOR-NIH (version 2.40)57,58. The 20 lowest energy structures were selected and
used to produce a final average structure. In the case of CARA generating
ambiguous NOE assignments, we applied the annealing protocol in Dynamo.
Unambiguous NOEs only were used in this case, after being classified as strong,
medium and weak on the base of their relative intensity in the NOESY spectra.
Using this classification, upper limits of 0.27, 0.33 and 0.50 nm were applied,
respectively, as restraint on the corresponding inter-proton distance. One thousand
structures were calculated and the 100 conformers with the lowest potential energy
were selected, aligned, and the root mean square deviation of the backbone heavy
atoms calculated with respect to their average structure. Solvent molecules were not
included in the calculations. Structural coordinates were deposited in the Protein
Data Bank (www.rcsb.org) and Biological Magnetic Resonance Bank (BMRB; www.
bmrb.wisc.edu) under accession codes of 6RSF and 6RSG (PDB) and 34404 and
34405 (BRMB) for pleurocidin-KR and pleurocidin-VA, respectively. Refinement
statistics are presented in the supplementary material (Supplementary Table 1).
Molecular dynamics simulations. Simulations were carried out on either the
ARCHER Cray XC30 supercomputer, or Dell Precision quad core T3400 or T3500
workstations equipped with a 1 kW Power supply (PSU) and two NVIDA PNY
GeForce GTX570 or GTX580 graphics cards using Gromacs59. The CHARMM36
all-atom force field was used in all simulations60–62. All membranes in this project
contained a total of 512 lipids, composed either of POPE/POPG (75:25 mol:mol) or
POPG. Eight peptides were inserted at least 30 Angstrom above the lipid bilayer in
a random position and orientation, at least 20 Angstrom apart. The starting
structures were taken from the NMR calculation in SDS micelles. The system was
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solvated with TIP3P water and Na+ ions added to neutralise. Energy minimisation
was carried out at 310 K with the Nose-Hoover thermostat using the steepest
descent algorithm until the maximum force was less than 1000.0 kJ/ml/nm
(~3000–4000 steps). Equilibration was carried out using the NVT ensemble for
100 ps and then the NPT ensemble for 1000 ps with position restraints on the
peptides. Hydrogen-containing bond angles were constrained with the LINCS
algorithm. Final simulations were run in the NPT ensemble using 2-fs intervals,
with trajectories recorded every 2 ps. All simulations were run for a total of 200 ns
and repeated twice, with peptides inserted at different positions and orientations,
giving a total of ~4.0 µs simulation. Torsion angles are circular quantities, and the
circular mean of psi or phi angles may be calculated as follows:












Similarly, the associated circular variance for psi or phi angles is calculated as
follows:
Var (ψ) = 1− Rav












Liposome preparation and circular dichroism spectroscopy. Far-UV CD spectra
of the peptides bound to small unilamellar vesicles (SUV) were obtained using a
Chirascan Plus spectrometer (Applied Photophysics, Leatherhead, UK) with
samples maintained at 310 K. To prepare SUV, lipid powders were solubilized in
chloroform and dried under rotor-evaporation. To completely remove the organic
solvent, the lipid films were left overnight under vacuum and hydrate in 5 mM Tris
buffer (pH 7.0). The lipid suspension was subjected to five rapid freeze–thaw cycles
for further sample homogenisation. POPE/POPG (75:25, mol:mol) and POPG
SUVs were obtained by sonicating the lipid suspension on Soniprep 150 (Mea-
suring and Scientific Equipment, London, UK) for 3 × 7 min with amplitude of six
microns in the presence of ice to avoid lipid degradation. The SUVs were stored at
4 °C and used within 5 days of preparation. Far-UV CD spectra were recorded
from 260 to 190 nm. SUV suspension was added to a 0.5 mm cuvette at a final
concentration of 5.0 mM and then a few μl of a concentrated peptide solution were
added and thoroughly mixed to give a final peptide concentration of 50 μM. The
same experimental conditions were used to investigate peptide secondary structure
in SDS micelles, while the SDS micelles concentration was 20 with 200 µM peptide.
In processing, a spectrum of the peptide free lipid suspension or SDS solution was
subtracted and Savitsky-Golay smoothing with a convolution width of 5 points
applied.
Electrophysiology experiments (Patch-clamp). As in our earlier work20, lipids
with diphytanoyl chains are used here to form giant unilamellar vesicles (GUV).
GUVs composed of DPhPE/DPhPG (60:40, mol:mol) and DPhPG were prepared
in the presence of 1M sorbitol by the electroformation method in an indium-tin
oxide coated glass chamber connected to the Nanion Vesicle Prep Pro setup
(Nanion Technologies GmbH, Munich, Germany) using a peak-to-peak AC vol-
tage of 3 V, at a frequency of 5 Hz, for 120 and 140 min, respectively, at 37 °C.
Bilayers were formed by adding the GUV solution to a buffer containing 250 mM
KCl, 50 mM MgCl2 and 10 mM Hepes (pH 7.00) onto an aperture in a borosilicate
chip (Port-a-Patch®; Nanion Technologies) and applying 70–90 mbar negative
pressure resulting in a solvent-free membrane with a resistance in the GΩ range.
After formation, a small amount of peptide stock solution (in water) was added to
50 μL of buffer solution to obtain its active concentration. All the experiments were
carried on with a positive holding potential of 50 mV. The active concentration, the
concentration at which the peptide first showed membrane activity, for each
peptide was obtained through a titration performed in the same conditions. For all
the experiments a minimum of six according repeats was done. Current traces were
recorded at a sampling rate of 50 kHz using an EPC-10 amplifier from HEKA
Elektronik (Lambrecht, Germany). The system was computer controlled by the
PatchControl™ software (Nanion) and GePulse (Michael Pusch, Genoa, Italy). The
data were filtered using the built-in Bessel filter of the EPC-10 at a cut-off fre-
quency of 10 kHz. The experiments were performed at room temperature. Data
analysis was performed with the pClamp 10 software package (Axon Instruments)
with estimation of pore radii performed according to the method of Tosatto et al.63.
Metabolomics sample preparation. S. aureus EMRSA-15 and P. aeruginosa RP73
were streaked on Mueller Hinton agar plates and RPMI (supplemented with 5%
FBS) agar plates and incubated at 37 °C overnight or until single colonies formed.
On three separate occasions, three single colonies were used to inoculate 10 ml of
respective media and challenges set up in broth using sub-inhibitory concentra-
tions of: D-pleurocidin, D-pleurocidin-VA, D-pleurocidin-KR or the antibiotic
tobramycin. Cultures were incubated overnight at 37 °C without shaking and
pelleted by centrifugation at 4 °C. The supernatant was removed and filtered
separately for spent media analysis, the pellet was briefly washed three times with
phosphate buffered saline (PBS). The pellets were frozen in liquid nitrogen and
lyophilised overnight in an Alpha 1–2 LD plus freeze dryer (Martin Christ, Ger-
many) and stored at −20 °C until required. Samples were transferred into HR-MAS
inserts for use in 4 mm Bruker MAS rotor and resuspended in 30 μl of D2O
containing 3-(Trimethylsilyl)propionic-2,2,3,3-D4 acid sodium salt (TMSP-2,2,3,3-
D4). The removed supernatant was filtered through 0.2 μm filters and pH adjusted
to within 0.3 pH units within the same sample set. The samples were supplemented
with 10% D2O containing TMSP-2,2,3,3-D4 and loaded into 5.0 mm NMR tubes.
HR-MAS NMR. NMR spectra were collected at 600MHz for 1H on a Bruker
Avance II spectrometer (Bruker Biospin, Coventry, UK) with a 4 mm HR-MAS
probe at 310 K while spinning at 5 kHz. 1H NMR spectra were acquired using a
Carr-Purcell Meiboom-Gill pre-saturation (cpmgpr1d) pulse sequence with a
spectrum width of 16.0 ppm and 9615 data points using 64 transients. Free
induction decay was multiplied by an exponential function with 0.293 Hz line
broadening. 2D 1H–1H correlation spectroscopy (COSY) and 1H–13C Hetero-
nuclear Single Quantum Correlation (HSQC) experiments were performed on
representative datasets using standard Bruker settings.
2,7-dichlorodihydrofluorescein diacetate (DCFH-DA) fluorescence. EMRSA-
15 and P. aeruginosa RP73 were cultured overnight at 37 °C in either MHB or
RPMI (5% FBS) in the presence and absence of D-pleurocidin or its analogues.
Samples were pelleted by centrifugation and diluted to an OD600 of 0.6 in PBS. The
cell suspension was incubated in darkness for 1 h at 37 °C with 5 µM DCFH-DA.
Upon completion of incubation, the cell suspension was washed with PBS to
remove excess dye and incubated in darkness at 37 °C for 5 min to equilibrate.
Fluorescence spectra (515–545 nm) were obtained using a Varian Cary Eclipse
fluorescence spectrometer at 37 °C with excitation at 485 nm. Statistical analysis
was by one-way ANOVA with Tukey’s post-hoc test.
Liquid state NMR. 1H NMR spectra were acquired under automation at 298 K and
700MHz on a Bruker Avance II 700 NMR spectrometer (Bruker Biospin, Cov-
entry, UK) equipped with a 5 mm QCl helium-cooled cryoprobe and a cooled
SampleJet sample changer. 1D CPMG-presat (cpmgpr1d) experiments were
acquired with 32 transients, a spectral width of 19.8 ppm and 11,904 data points.
2D 1H-1H COSY and 1H-13C HSQC experiments were performed on repre-
sentative datasets using standard Bruker settings.
Data processing. The spectra were Fourier transformed automatically using
standard Bruker commands and manually phased and baseline corrected in Bruker
TopSpin 4.0 (Bruker Biospin, Coventry, UK). Spectral pre-processing, cross-
validation and multivariate analysis were carried out using the in-house pro-
gramme developed by Dr Louic Vermeer and MVAPACK, an opensource Octave
library for NMR metabolomic data processing and analysis64. Pre-processing
modifies NMR spectra and reduces the variances and influences which are not of
interest and may interfere with data analysis, for example, residual water peak or
noise and the TSP reference peak. Initially a principle component analysis was
carried out to identify clustering spectra and potential outliers in the data, due to
e.g. poor baseline. Data were then subject to probabilistic quotient normalisation
before binning and alignment. Orthogonal Projections to Latent Structures Dis-
criminant Analysis analyses were conducted to establish the quality of binary
comparisons of the metabolomic data (Supplementary Table 4). Volcano plots were
made using the binned data for every control sample (no AMP or tobramycin)
versus challenge sample (with an AMP or tobramycin), comparing fold changes in
metabolites, defined as the ratio between the control and the challenge. The
Mann–Whitney U test was used to compare means and associated p values were
false discovery rate adjusted using the Benjamini-Hochberg method (α= 0.05).
Box plots were generated using changes in normalised intensity for each metabolite
and significant differences between challenges and controls were determined using
a one-way ANOVA. Volcano plots and box plots were generated using in-house
software developed for Jupyter Notepad using Python 3.7.0. Metabolites were
assigned using the databanks: Chenomx NMR suite software (Chenomx Inc.,
Canada), Human Metabolome Database, BMRB, E. coli Metabolome Database and
AOCS lipid library; and a comparison of chemical shifts to the literature, which was
confirmed using 2D NMR spectra. Annotated spectra can be found in the sup-
plementary materials (Supplementary Fig. 15). Metaboanalyst and KEGG were
later used to identify key pathways that may be affected by these metabolites.
Murine EMRSA-15 lung infection model. Using the recently developed method65,
an overnight culture of EMRSA-15 was prepared in tryptic soy broth (TSB).
EMRSA-15 was cultured in TSB overnight at 37 °C, adjusted to a starting OD600 of
0.025, and grown for additional 4 h for agar beads preparation. EMRSA-15 was
embedded into agar beads by mixing the overnight culture with molten tryptic soy
agar, which was then spun into warmed mineral oil. The preparation was cooled
and centrifuged at 2700 × g, the remaining oil was eliminated, and the beads were
washed in sterile PBS. The CFU content of the beads slurry was subsequently
quantified on TSA plates and the beads slurry then diluted to 2 × 107 CFU/ml in
sterile PBS to deliver a final dose of 1 × 106 CFU/mouse. Animal work was per-
formed in accordance with the Animals (Scientific Procedures) Act of 1986 (United
Kingdom) and 2012 revisions with local ethical approval of King’s College London.
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On day 0, male C57Bl6J mice (8–10 weeks, Charles River) were anaesthetised
under Isoflurane and 50 µl inoculum of EMRSA-15 embedded in agar beads
(106 CFU/mouse) was instilled directly into the respiratory tract via oropharyngeal
dosing (o.a.). Sham control mice were inoculated with sterile PBS agar beads.
Animals were treated with either Vehicle (Saline), 200 mg/kg vancomycin or 0.05,
0.5 or 5 mg/kg D-pleurocidin-KR at 4, 24 and 30 h post infection via intravenous
injection, reaching a total dosage of 600 mg/kg vancomycin or 0.15, 1.5 or 15 mg/kg
D-pleurocidin-KR. Body weight was measured daily, and animals monitored at
regular intervals for signs of pain and distress. After 48 h of pulmonary infection,
animals were terminally euthanized using 25% urethane via intra-peritoneal
injection. CFUs were quantified in lung homogenates. Lung homogenates were
then centrifuged at 14000 rpm for 30 min at 4 °C and the supernatants were stored
at −80 °C for future analysis. For BAL fluid collection and analysis (total and
differential cell count), a 22-gauge catheter was inserted into the trachea and BAL
was recovered by instillation of 0.5 ml of sterile PBS three times and total cells
counts were performed by adding Turks stain in a 1:1 ratio. BAL fluid was then
centrifuged, and supernatants were stored at −20 °C. Total levels of TNFα, IL-6,
KC and MCP-1 were quantified from BAL fluid collected from all animals and
measured by ELISA according to the manufacturer protocol (R&D Systems UK).
Concentrations of all mediators were then normalised to total protein content of
BAL fluid quantified via bicinchoninic acid total protein assays performed to
manufacturers protocols (Thermofisher Scientific). Data presented are an aggregate
of two independent repeats, each with control groups (n= 6) and peptide treat-
ment groups (n= 4). Statistical analysis was by one-way ANOVA with Dunnett’s
multiple comparisons test.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Supplementary Information including more extensive analysis of the MD simulation
data, Circular Dichroism experiments and both liquid and HR-MAS NMR metabolomic
data are available. Structural coordinates were deposited in the Protein Data Bank (www.
rcsb.org) and Biological Magnetic Resonance Bank (BMRB; www.bmrb.wisc.edu) under
accession codes of 6RSF and 6RSG (PDB) and 34404 and 34405 (BRMB) for pleurocidin-
KR and pleurocidin-VA, respectively. In addition to the structural coordinates the
datasets generated during and/or analysed during the current study are available from the
corresponding author on reasonable request while the data presented in the main
manuscript figures are available as Supplementary Data.
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